Independent U.S. Market Research

Biotech Catalysts, Stock Hubs & U.S. Small/Mid-Cap Research

Merlintrader publishes independent educational research on U.S.-listed biotech and small- and mid-cap stocks, with daily market briefings, FDA and PDUFA tracking, catalyst calendars and dedicated company hubs across biotech, space, defense, AI, cannabis, energy and critical minerals.

SUNDAY MORNING — AUGUST 30, 2026

The week ended with a hawkish keynote, and the things that moved hardest were not the indices: the front end of the curve, precious metals, semiconductors and biotech

United States markets are shut and reopen on Monday, August 31, the last session of the month. What follows separates what the tape actually repriced on Friday from what has arrived since: a first-in-class approval granted after the closing bell, a Chapter 11 petition with a named stalking horse bidder, an oil agreement announced from the White House into a Gulf that has been shipping at a fraction of its normal rate, and the second and third days of the cardiology congress in Munich. Every United States equity and exchange-traded fund price below is an official closing mark for Friday, August 28, 2026, unless it is explicitly labelled as a live weekend quotation.

WHAT FRIDAY ACTUALLY REPRICED
  • The index level barely moved and the composition underneath it did. The Dow fund $DIA closed 535.06, down 0.03 percent, and the S&P 500 fund $SPY closed 769.35, down 0.23 percent, while the small-cap fund $IWM closed 295.75, down 1.35 percent. A sixth of a percent separated the two large-cap funds; a full point and a third separated them from small caps.TAPE
  • Two sectors carried the whole of the damage. The semiconductor fund $SMH closed 553.11, down 3.47 percent, and the biotechnology fund $XBI closed 162.38, down 3.48 percent. The Nasdaq 100 fund $QQQ closed 716.43, down 0.65 percent, which is what happens when a heavily weighted group falls three and a half percent and the rest of the index absorbs it.TAPE
  • Precious metals took the largest single move of the day. The gold fund $GLD closed 408.89, down 3.24 percent, on 25.0 million shares, and the silver fund $SLV closed 60.02, down 4.38 percent, on 36.2 million shares. The dollar fund $UUP closed 28.18, up 0.57 percent. A hawkish reading of policy is the ordinary explanation for that pairing; it is offered here as the ordinary explanation and not as a verified cause.METALS
  • The move in Treasuries was concentrated at the short end, which is the part of the curve that carries policy expectations. Between Thursday and Friday the one-year settled par yield went from 4.04 to 4.15 percent and the two-year from 4.20 to 4.34, while the ten-year went from 4.67 to 4.73 and the thirty-year from 5.19 to 5.22. Fourteen basis points at two years against six at ten years is a curve being flattened from the front, not a term-premium story.RATES
  • The arithmetic of that is worth stating plainly: the gap between the two-year and the ten-year closed the week at 39 basis points, against 47 the day before. The long-bond fund $TLT closed 82.88, down 0.30 percent, which is a modest loss for a day on which the whole curve moved up.RATES
  • Volatility rose but did not spike. The short-term volatility futures note $VXX closed 18.36, up 1.44 percent. Two corners of the market finished green: the energy sector fund $XLE closed 62.68, up 0.63 percent, and the United States cannabis fund $MSOS closed 4.99, up 3.31 percent on 8.9 million shares.TAPE
A FIRST-IN-CLASS APPROVAL, GRANTED AFTER THE BELL
  • The Food and Drug Administration approved Mimrylo, rusfertide, on Friday for adults with polycythemia vera, a rare disorder in which the body overproduces red blood cells. It is the first approved treatment in that disease that mimics hepcidin, the hormone regulating how much iron the body makes available; by limiting that iron it limits red-cell production. The approval was granted to Takeda Pharmaceuticals America and carried priority review.APPROVAL
  • The evidence base is VERIFY, a multicentre randomised double-blind placebo-controlled Phase 3 study in 293 adults who still required frequent phlebotomies despite standard-of-care therapy. Patients were randomised one to one over 32 weeks, starting at 19 milligrams subcutaneously once weekly and titrated to hold haematocrit below 45 percent. Measured on the proportion of patients not meeting phlebotomy criteria between weeks 20 and 32, 76.9 percent on treatment required none against 32.9 percent on placebo. The most common adverse reactions were injection-site reactions and anaemia.APPROVAL
  • The commercial consequence sits with the partner rather than the marketer. Protagonist Therapeutics announced on April 28 that it had opted out of the fifty-fifty United States profit and loss share with Takeda. Its own quarterly report states that the opt-out election triggered a 200.0 million dollar payment, with a further 200.0 million dollar opt-out fee and a separate 75.0 million dollar milestone due on approval. Friday’s decision is the event those two obligations were written against.APPROVAL
  • The same filing sets out what remains after the cash: eligibility for up to 775.0 million dollars in sales milestones and tiered royalties of 14 to 29 percent on annual worldwide net sales, a weighted average of approximately 21 percent at 1.5 billion dollars of annual net sales, with the 29 percent tier applying to incremental sales above that level. $PTGX closed 144.33, down 3.46 percent on 501,247 shares, hours before the approval was public. $TAK closed 18.03, unchanged.APPROVAL
A CHAPTER 11, WITH THE BUYER ALREADY NAMED
  • BioXcel Therapeutics and its subsidiaries OnkosXcel Therapeutics and OnkosXcel Employee Holdings filed voluntary petitions under Chapter 11 in the United States Bankruptcy Court for the District of Delaware on August 27, and disclosed it to the Securities and Exchange Commission at 06:00 Coordinated Universal Time on Friday. The debtors continue to operate as debtors-in-possession. $BTAI closed 0.18, down 74.76 percent, on 58.6 million shares.BANKRUPTCY
  • The financing to run the case comes from the same lenders as before the case. Affiliates of Oaktree Capital Management and the Qatar Investment Authority, the prepetition lenders under the April 2022 credit agreement, are expected to provide up to 19 million dollars of new money in two draws of 9.5 million each, one on the interim order and one on the final, together with up to 58.25 million dollars of roll-up loans converting prepetition obligations dollar for dollar.BANKRUPTCY
  • A stalking horse agreement was signed the same day with Teva Pharmaceuticals International, guaranteed by Teva Pharmaceutical Industries. The terms are 57.5 million dollars of upfront cash, assumption of specified liabilities, up to 67.5 million dollars of development milestones tied to the outcome and timing of the pending supplemental application for at-home use of IGALMI, and up to 20 million dollars of commercial milestones on net-sales thresholds after closing. $TEVA closed 36.44, down 3.14 percent.BANKRUPTCY
  • A stalking horse bid is a floor, not a sale. The offer stands as the minimum bid into a Section 363 auction and remains subject to higher or otherwise better bids, to court approval of the bidding procedures and of the transaction, and to an outside date of October 30, 2026 after which either side may walk. The company also appointed Samir Saleem as Chief Restructuring Officer, reporting to a strategic process committee of the board.BANKRUPTCY
AN OIL DEAL, INTO A STRAIT THAT IS NOT WORKING
  • The President announced on Friday an agreement with Venezuela covering 17 fields, described as holding a proven potential of 65 billion barrels, under hundred-year concessions granted to a new private joint venture. The reported structure gives the United States an effective 55 percent share of output, split between equity in the venture’s holding company and crude delivered to the United States government at cost for the Strategic Petroleum Reserve and for military use. The negotiation is attributed to the State Department and the Pentagon.ENERGY
  • These figures come from the announcement and from first-tier press accounts of it, not from a filed document, and no company party has yet put them in a disclosure. Treat the structure as announced rather than as executed until a signed instrument exists.ENERGY
  • The context that makes an announcement of that size legible is the Gulf. Reported vessel counts through the Strait of Hormuz averaged roughly five a day between mid-July and August 23, against pre-war traffic, with regional crude exports reported down by nearly half from about 17 million barrels a day in 2025 to roughly nine million now. Those are press estimates from shipping data and are carried here as such.ENERGY
  • Spot crude has been elevated without being disorderly. The Energy Information Administration’s daily West Texas Intermediate series prints 83.90 dollars a barrel for August 25, against 86.34 on August 24 and a recent high of 89.75 on August 20. The oil fund $USO closed 129.70, down 0.24 percent, and the exploration and production fund $XOP closed 185.94, up 0.25 percent.ENERGY
  • Agricultural futures funds went the other way from metals on the same session. The wheat fund $WEAT closed 28.00, up 2.87 percent, the corn fund $CORN closed 19.95, up 0.76 percent, and the broad agriculture fund $DBA closed 29.19, up 1.28 percent. Uranium was the week’s worst commodity proxy: $URA closed 45.57, down 5.79 percent.COMMODITIES
MUNICH, DAYS TWO AND THREE
  • Cytokinetics released a second set of results on Saturday, covering additional analyses from ACACIA-HCM on cardiac structure and diastolic function in non-obstructive hypertrophic cardiomyopathy, and a new analysis of MAPLE-HCM comparing aficamten with metoprolol across pre-trial treatment groups in the obstructive form. The numerical detail of those Saturday presentations could not be read against a primary document at the time of writing and is therefore described without figures here. $CYTK closed 72.09, down 7.46 percent, on Friday.READOUT
  • Bristol Myers Squibb presented long-term efficacy and safety data on Camzyos extending to five years at the same congress on Saturday. $BMY closed 66.58, down 0.55 percent.READOUT
  • The congress closes in Munich on Monday, August 31. Anything presented between now and then reaches a market that cannot act on it until the opening bell, which is the structural feature of a European medical meeting held across a weekend.CALENDAR
THE ONE MARKET THAT DID NOT CLOSE
  • At 06:45 Coordinated Universal Time this morning, Coinbase showed bitcoin against the dollar last at 78,255.32, inside a twenty-four hour range of 77,433.28 to 78,334.44 from an open of 77,459.99. Ether was last at 2,459.89 and solana at 105.01. These are live marks and will have moved by the time they are read.CRYPTO
  • The range is the point rather than the level: roughly nine hundred dollars from low to high across a full weekend day, on a market that trades continuously and has had no session boundary to hide behind since Friday’s close in equities. Bitcoin has still not traded back above 80,000 in that window.CRYPTO
WHAT THE WEEK OPENS INTO
  • Monday, August 31 is the last session of the month, and month-end rebalancing tends to concentrate flow into the close rather than spread it across the day. United States markets are open all five sessions this week; Labor Day falls on September 7.CALENDAR
  • The manufacturing survey from the Institute for Supply Management is published on Tuesday, September 1 at 10:00 New York time, and the services survey follows on Thursday, September 3 at the same hour. After a keynote read as hawkish, these are the first hard readings the market gets on whether activity supports that reading.MACRO
  • The August Employment Situation is released on Friday, September 4 at 8:30 New York time. It is the last full labour reading before the Federal Open Market Committee meets on September 15 and 16 with a Summary of Economic Projections, which is why a fourteen basis point move at two years on Friday was not an overreaction to a speech.MACRO
  • Broadcom reports third-quarter fiscal 2026 results on Wednesday, September 2 after the close, with company guidance of approximately 29.4 billion dollars in revenue. It lands into a semiconductor group that gave up 3.47 percent on Friday, which sets a lower bar and a more nervous audience than the same print would have met a week ago.EARNINGS
  • Two watchlist names carry unresolved situations into Monday: BioXcel, whose bidding procedures now go before a Delaware judge, and Protagonist, whose approval landed after the last bell of the week and has not yet traded.WATCH
METHOD

United States equity and exchange-traded fund prices in this edition are official closing marks for Friday, August 28, 2026 taken from the Finviz Elite feed, with percentage changes measured against the August 27 close. Treasury yields are settled daily par yield curve rates published by the United States Department of the Treasury. The rusfertide approval, the VERIFY trial design and its results are read from the Food and Drug Administration news release of August 28, 2026 and the registration record for study NCT05210790. The Protagonist collaboration economics are read from the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026, filed with the Securities and Exchange Commission on August 5, 2026. The BioXcel petition, the debtor-in-possession financing and the stalking horse agreement are read from the Current Report on Form 8-K filed by BioXcel Therapeutics on August 28, 2026; the filing time quoted is the acceptance timestamp recorded by the Commission. The West Texas Intermediate spot series is the daily series published by the Energy Information Administration, quoted with its own date because it lags the equity session. The digital-asset quotations are taken live from the Coinbase Exchange public market data endpoint at the time stated and are not closing prices. The release dates for the Institute for Supply Management surveys, the Employment Situation and the Federal Open Market Committee meeting are from the published calendars of those bodies, and the Broadcom date and revenue guidance are from the company’s own announcement. Not verified against a primary source and therefore carried without figures of its own: the numerical detail of the Cytokinetics and Bristol Myers Squibb presentations of August 29; the terms of the Venezuela oil agreement, which are reported rather than filed; the Strait of Hormuz traffic and Gulf export estimates, which are press calculations from shipping data; and the attribution of Friday’s moves in any individual security to any single cause. No European or Asian index levels are included because none could be verified against a primary source at the time of writing.

Read the extended Daily BriefingWeekly Market Pulse

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: August 25 → September 30, 2026. Compact homepage board for unresolved FDA decisions, regulatory submissions and major clinical readouts. A prior-date item remains visible only when the regulatory process is still materially open; catalysts resolved in the past few days are retained briefly for continuity. October and later events are excluded from this widget.

29On board
14FDA / Reg
15Data / Filing
Aug 29Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$JAZZ Ziihera combo Aug 25 Approved FDA approval in first-line HER2-positive GEA

Jazz Pharmaceuticals. On August 25, 2026 the FDA approved Ziihera (zanidatamab-hrii) in two first-line regimens for locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma: with tislelizumab and fluoropyrimidine- and platinum-based chemotherapy for IHC 3+ and IHC 2+/ISH+ tumours, and with chemotherapy alone for IHC 3+ tumours. The decision landed on the Priority Review goal date. Approval rests on the Phase 3 HERIZON-GEA-01 trial, where median progression-free survival was 12.4 months against 8.1 months and median overall survival 26.4 months against 19.2 months. The label carries a boxed warning for diarrhoea and embryo-fetal toxicity. Zanidatamab was discovered by Zymeworks ($ZYME), which confirmed the approval the same day.

$NRXP KETAFREE Ongoing FDA review First-cycle review complete; manufacturer vial attestation submitted

NRx Pharmaceuticals. The July 29 GDUFA goal date has passed, but the ANDA remains active. On August 7 the company reported that FDA had completed its first-cycle review of the preservative-free intravenous ketamine ANDA with no major deficiencies related to the drug product, ingredients, proposed labeling, CMC or other drug-related review matters. The sole remaining major deficiency involved the container-closure system and a manufacturer attestation concerning the luer-lock vial. The same vial is used in three approved ANDA products that collectively shipped 11.9 million units in the United States over the prior 12 months, and the filing included testing of more than 3,500 vials from seven lots without observed luer-lock failures. On August 17 NRx confirmed that the requested attestation had been submitted. No company release has followed since August 17 and no new exact action date has been disclosed.

$GILD Bixlenvo Aug 27 Approved FDA approval of a once-daily single tablet regimen for HIV

Gilead. On August 27, 2026, on the Priority Review goal date, the FDA approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg) as a complete regimen for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen with no known or suspected resistance to either component. It is the first and only single tablet regimen for virologically suppressed people on complex regimens. Approval rests on the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials, where the combination maintained virologic suppression at week 48; the most common adverse reactions were headache, nausea and diarrhoea. Dosing starts with a two-day initiation regimen taken with Sunlenca. The combination is not approved by any regulator outside the United States.

$PTGX rusfertide Aug NDA Polycythemia vera · company guidance now says August, and no decision has been announced

Protagonist / Takeda. The rusfertide NDA in polycythemia vera is under Priority Review and no FDA decision had been announced as of August 25. The most recent primary-source wording is narrower than the original one: Protagonist’s second-quarter release and Form 10-Q, both dated August 5, 2026, state that the application carries “a Prescription Drug User Fee Act target action date in August 2026”. The earlier joint Takeda and Protagonist announcement of March 2, 2026 had placed the goal date in the third quarter without naming a month. The exact day has never been made public, so the window is closing, or has closed, without an announcement. Rusfertide also holds Breakthrough Therapy, Orphan Drug and Fast Track designations, and the submission rests on the Phase 3 VERIFY study with the Phase 2 REVIVE study and the THRIVE long-term extension.

$TLX Pixclara Sep 11 PDUFA FDA decision on the resubmitted Pixclara NDA

Telix Pharmaceuticals. September 11, 2026 is the FDA goal date for the resubmitted Pixclara (TLX101-Px) NDA, reconfirmed by the company in the half-year announcement filed on Form 6-K on August 20, 2026. The application was resubmitted in March and accepted in April, so the September catalyst is the decision on that NDA, not the filing itself. Pixclara is a PET imaging agent intended to help characterise suspected recurrent or progressive glioma against treatment-related changes. In the same document Telix confirmed that the Zircaix BLA has still to be resubmitted.

$RARE UX111 Sep 19 BLA Gene therapy for Sanfilippo syndrome type A

Ultragenyx. PDUFA for the resubmitted UX111 (rebisufligene etisparvovec) BLA in Sanfilippo syndrome type A, seeking accelerated approval. The date was set with the acceptance of the BLA resubmission and the company reaffirmed it in its August 4 update; no extension has been announced since. The August 19 accelerated approval of GENGLYCOS in glycogen storage disease type Ia is a separate programme and does not change this review.

$MRK WINREVAIR Sep 21 sBLA PAH · HYPERION-based label update

Merck. PDUFA for a supplemental BLA seeking a U.S. label update for WINREVAIR (sotatercept-csrk) based on the Phase 3 HYPERION study in pulmonary arterial hypertension. The September 21 date is stated in the Form 10-Q filed on August 7, 2026, and nothing published since changes it.

$IONS zilganersen Sep 22 NDA Alexander disease · Priority Review

Ionis. Priority Review PDUFA for the zilganersen NDA in Alexander disease, a rare progressive neurological disorder. The date is confirmed in the Form 10-Q filed on July 29, 2026. Ionis is preparing to commercialise the product itself in the United States, while ex-U.S. rights were licensed to Recordati in June 2026. It remains one of September’s most closely watched rare-disease decisions.

$GRAL Galleri Sep 23 FDA panel AdCom on the multi-cancer MCED test PMA

GRAIL. FDA’s Molecular and Clinical Genetics Panel is scheduled to meet on September 23, 2026 to discuss and vote on the Galleri premarket approval application. The meeting notice was published in the Federal Register on August 10, 2026, the session runs from 9:00 to 18:00 Eastern at White Oak in hybrid form, and public comments close on September 8. The FDA advisory committee calendar still carries the meeting with no postponement note. Galleri is a blood-based multi-cancer early detection test proposed for adults aged 50 and older; this is a device and diagnostics catalyst rather than a drug PDUFA, and it is the first FDA advisory committee ever convened on an MCED test.

$MIRM zilurgisertib Sep 26 NDA FOP · NDA rests on secondary endpoints

Mirum Pharmaceuticals / Incyte. Priority Review PDUFA for the zilurgisertib NDA in fibrodysplasia ossificans progressiva in patients aged 12 and older; the application is Incyte’s and Mirum holds exclusive worldwide rights under a licence signed in April 2026, with 25 million dollars due on FDA approval. The date is confirmed in Mirum’s Form 10-Q of August 5, 2026. The same filing states in its risk factors that “while the NDA for zilurgisertib is supported by secondary endpoints, the pivotal study did not reach statistical significance on the primary endpoint”. That pivotal study is the Phase 2 PROGRESS trial, whose results the company presented at ENDO 2026 without addressing the primary endpoint.

$BFRI Ameluz PDT Sep 28 sNDA Expansion into superficial basal cell carcinoma

Biofrontera. PDUFA for the Ameluz photodynamic-therapy sNDA in superficial basal cell carcinoma. The date comes from the filing-acceptance release of February 11, 2026, in which FDA identified no filing deficiencies, and the company reaffirmed a late-September action date in its second-quarter release of August 13, 2026, pointing to a launch in the first quarter of 2027. No filing or release has followed since.

$SRRK apitegromab Sep 30 BLA SMA · Catalent Indiana removed from the BLA on August 21

Scholar Rock. The apitegromab BLA in spinal muscular atrophy remains targeted to September 30. On August 21, 2026 the company said it had successfully removed Catalent Indiana as a commercial fill-finish facility from the BLA under FDA guidance, after Catalent notified customers on August 7 that its April inspection had been classified Official Action Indicated. In the same August 21 update Scholar Rock confirmed the action date as unchanged, said the European marketing authorisation application had been withdrawn following the CHMP written procedure of August 20 and would be resubmitted with the alternative site, and pointed to a Japanese filing by the end of 2026. Manufacturing and CMC risk therefore stays central to this review.

$ROIV brepocitinib Q3 NDA Dermatomyositis · Priority Review, exact day never disclosed

Priovant / Roivant. The brepocitinib NDA in dermatomyositis is under Priority Review. The acceptance release of March 3, 2026 states a target action date in the third quarter of 2026 and no exact day has ever been made public. Roivant’s quarterly update of August 6, 2026 describes the application as still under review and points to a commercial launch by the end of September if approval arrives.

$QURE AMT-130 Q3 BLA Huntington’s disease · filing plus four-year data in September

uniQure. The AMT-130 accelerated-approval BLA in Huntington’s disease was still to be filed as of August 25; the July 29, 2026 quarterly update describes U.S. and U.K. submissions as on track for the third quarter. Official minutes of the Type B meeting received in July confirm alignment on a filing based on existing clinical data with comparison to an external control, while the design of the confirmatory study was still being discussed. Topline four-year data from the Phase I/II study are expected in September 2026, which makes the quarter dense for this programme.

$IMMX NXC-201 Late Sep Data NEXICART-2 · AL amyloidosis

Immix Biopharma. The next NEXICART-2 update for NXC-201 in relapsed or refractory AL amyloidosis is expected in late September 2026, a window stated in the company release of May 21, 2026. Enrolment of 45 patients is complete, as confirmed in the Form 10-Q of August 7, 2026, and one-year follow-up data due by the end of March 2027 are expected to guide the BLA. The programme is designed to be registrational.

$KPTI selinexor combo Aug sNDA Selinexor plus ruxolitinib filing in myelofibrosis

Karyopharm. The company plans to submit the selinexor plus ruxolitinib sNDA in myelofibrosis during August under the accelerated-approval pathway, requesting Priority Review at the same time; FDA has given written feedback that SVR35 appears to qualify as a reasonably likely surrogate endpoint. The plan was reaffirmed in the second-quarter release of August 13, 2026 and no announcement confirming the submission has appeared since, so the filing itself is still the open event. The former endometrial-cancer catalyst is closed: XPORT-EC-042 missed its primary progression-free-survival endpoint on July 30.

$KOD DAYBREAK Sep Phase 3 Wet AMD · Zenkuda and KSI-501 against aflibercept

Kodiak Sciences. One-year primary-endpoint topline results from the Phase 3 DAYBREAK study in wet age-related macular degeneration are expected in September 2026, a guidance restated in the second-quarter release of August 13, 2026. The study evaluates Zenkuda (tarcocimab tedromer) and KSI-501 in parallel arms against aflibercept, and enrolment is complete. Cash stood at 125.9 million dollars at June 30 with runway stated into 2027, which raises the stakes on the readout.

$ALMS envudeucitinib Q3 Data LUMUS Phase 2b in systemic lupus erythematosus

Alumis. Potentially pivotal Phase 2b LUMUS results for envudeucitinib in systemic lupus erythematosus are expected in the third quarter, guidance repeated in the second-quarter release of August 13, 2026. The study is randomised, double-blind and placebo-controlled with BICLA as the primary endpoint. Decisions on Sjogren’s and cutaneous lupus are explicitly tied to this outcome, and for an autoimmune readout the market will weigh dose consistency and safety alongside statistical significance.

$IVVD VYD2311 Late Q3 Data DECLARATION pivotal study · enrolment complete

Invivyd. Topline data from the pivotal DECLARATION study of VYD2311 are planned later in the third quarter of 2026, per the second-quarter release of August 13, 2026, which also describes the study as approaching its planned analysis after being upsized to roughly 2,400 participants. Topline from LIBERTY is guided to the same window. Cash of 160.1 million dollars is stated as sufficient through the DECLARATION readout, and the company has flagged the July notice terminating the PEMGARDA emergency use authorisation with twelve months’ notice.

$PHVS deucrictibant XR Q3 Phase 3 CHAPTER-3 · hereditary angioedema prophylaxis

Pharvaris. Phase 3 CHAPTER-3 topline data for extended-release deucrictibant in hereditary-angioedema prophylaxis are expected in the third quarter of 2026, confirmed in the Form 6-K release of August 12, 2026, which puts randomisation at 85 participants assigned two to one to 40 mg daily or placebo over 24 weeks. It is one of the quarter’s most important registrational HAE readouts. Separately, the immediate-release NDA carries a PDUFA date of April 23, 2027.

$SYRE SPY003 Sep Data SKYLINE Part A in ulcerative colitis

Spyre Therapeutics. SPY003 Part A topline data from the Phase 2 SKYLINE study are expected in September 2026, as stated in the second-quarter release of August 4, 2026; enrolment of Part A is complete and SPY003 is the last of the three readouts, after SPY001 and SPY002 in April and June. The RA sub-study of SKYWAY is guided to the same month. With 1.145 billion dollars in cash and runway into the second half of 2029, financing risk is not the issue here.

$VERA TRUTAKNA / atacicept Q3 eGFR ORIGIN 3 final efficacy analysis

Vera Therapeutics. The ORIGIN 3 final efficacy analysis is expected in the third quarter, as restated in the second-quarter release of August 10, 2026. It follows the accelerated approval of TRUTAKNA (atacicept-vymj) on July 7, 2026, which rested on proteinuria, while ORIGIN 3 continues blinded and placebo-controlled with eGFR as the confirmatory endpoint. The timing was pulled forward from 2027 after alignment with FDA announced on June 2, 2026, and a supplemental BLA is guided to the fourth quarter. This is not another approval decision: what matters is the durability of the renal effect and the read-through for the confirmatory pathway.

$XENE azetukalner Q3 NDA Focal-onset seizure filing after the pre-NDA meeting

Xenon. The azetukalner NDA submission in focal-onset seizures is on track for the third quarter following the pre-NDA meeting with FDA, as stated in the second-quarter release of August 6, 2026. The application had not been filed as of August 25. Filing confirmation would open FDA’s filing-review stage and set up a later PDUFA assignment.

$BBIO infigratinib Aug 10 NDA submitted Achondroplasia · FDA filing acceptance is the next step

BridgeBio. BridgeBio confirmed on August 10, 2026 that it had submitted the NDA for oral infigratinib in achondroplasia, and its own pipeline table lists the next milestone as FDA setting a PDUFA date. Neither filing acceptance nor a PDUFA date had been announced as of August 25, so the programme stays on the board with the regulatory process materially open. Infigratinib holds Breakthrough Therapy, Fast Track and Rare Pediatric Disease designations, U.S. launch is guided to mid-2027 and a European application is planned for the fourth quarter.

$MLTX sonelokimab Late Sep BLA Hidradenitis suppurativa filing after positive IZAR-1

MoonLake. The sonelokimab BLA in hidradenitis suppurativa is expected around the end of September 2026, with the company guiding to a PDUFA date allocation and a decision on Priority Review by the end of November. The milestone table sits in the August 10, 2026 release that also carried positive topline results from the Phase 3 IZAR-1 trial. The filing had not been announced as of August 25.

$BNTX pumitamig · WCLC Sep 12-15 Data WCLC 2026 · PRESERVE-003 overall survival update

BioNTech. On August 20, 2026 the company disclosed its programme for the World Conference on Lung Cancer in Seoul, held from September 12 to 15, 2026. It includes a late-breaking oral presentation with the first data on the combination of pumitamig and elfetabart drozuntecan, and an overall survival update from the Phase 3 PRESERVE-003 study of gotistobart in squamous non-small cell lung cancer. Conference presentations are not regulatory events, but for this programme they are the readout of the quarter.

$SMMT ivonescimab · WCLC Sep 15 Data WCLC 2026 · updated HARMONi overall survival, two months before the PDUFA

Summit Therapeutics. On August 25, 2026 Summit said the updated overall-survival follow-up from the global Phase III HARMONi study will be presented at the IASLC World Conference on Lung Cancer on September 15, 2026, in session OA14, abstract OA14.04. The same day the company announced publication of the HARMONi primary analysis in The Lancet Oncology: median progression-free survival 6.8 against 4.4 months, hazard ratio 0.52 (95% CI 0.41–0.66; p<0.0001), with the primary overall-survival analysis showing a positive trend that did not reach statistical significance. The FDA has told the company a statistically significant overall-survival benefit is necessary in this setting, which is what makes a survival update three weeks before the November 14 target action date the readout to watch. Partner Akeso separately reported a statistically significant overall-survival benefit in first-line advanced biliary tract cancer (HARMONi-GI1), a single-region China study run and analysed by Akeso.

$RGNX RGX-202 · Duchenne Q3 BLA Duchenne BLA submission still guided to this quarter, after the RGX-121 hold

REGENXBIO. On August 24, 2026 the FDA placed a clinical hold on the Phase I/II/III trial of RGX-121 in mucopolysaccharidosis type II, following asymptomatic spine MRI findings in five participants of the CAMPSIITE study, and the company said it does not expect to resubmit the RGX-121 Biologics License Application in the near term. In the same release it stated that the Duchenne and retinal programmes use a different capsid and different routes of administration, and that their near-term catalysts are on track: the planned submission of the Duchenne BLA this quarter, and wet AMD topline pivotal data in the fourth quarter. Investigators deemed the spine findings non-serious and radiologists believe they are likely benign; no brain nodules or masses were identified. The stock fell sharply on the hold, which makes the Duchenne filing the near-term item that either confirms or undermines the company’s separation of the two programmes.

$GOSS seralutinib Sep NDA PAH filing tied to a 125 million dollar financing tranche

Gossamer Bio. On August 21, 2026 the company said it expects to submit the seralutinib NDA in pulmonary arterial hypertension in September 2026. The filing carries a direct financial consequence: the 250 million dollar private placement announced alongside it is structured so that a second tranche of roughly 125 million dollars unlocks on FDA acceptance of the application within 2026. Submission and acceptance are therefore two distinct events to track.

Most attention-worthy watchlist

$NRXP $PTGX $GILD $RARE $IONS $GRAL $MIRM $SRRK $PHVS $QURE $IMMX

Board rule

Only future or still materially unresolved catalysts through September are shown; catalysts resolved in the past few days are retained briefly for continuity. $JAZZ/Ziihera stays for one update: the FDA approved it on August 25 in first-line HER2-positive gastroesophageal adenocarcinoma, on its goal date. $CAPR has been removed from the grid. On August 24 the FDA extended the deramiocel PDUFA target action date from August 22 to November 22, 2026, after Capricor filed a BLA amendment with 24-month HOPE-3 open-label-extension data supporting a refined indication focused on upper limb function; CBER classified the submission as a major amendment. The new date falls outside the window this widget covers. $REGN/Pasatru and $RARE/GENGLYCOS have rolled off after one update: both were approved on August 19, the second for FOP and the first gene therapy in Ultragenyx history respectively. $PTGX has been corrected from Q3 back to August. The company’s own second-quarter release and Form 10-Q of August 5 both state a target action date in August 2026, which supersedes the March 2 wording of a third-quarter goal date; the exact day has never been published and no decision has been announced. $SRRK has been corrected as well: the removal of Catalent Indiana from the BLA was announced on August 21, not on August 7, which is the date Catalent notified customers of the Official Action Indicated classification. $BNTX and $GOSS join the board: BioNTech disclosed its WCLC programme on August 20 with a PRESERVE-003 overall survival update, and Gossamer Bio guided on August 21 to a September seralutinib filing. $NRXP remains because the manufacturer vial attestation has been submitted but no new exact action date has been disclosed and no company release has followed since August 17. $KPTI stays on an August window because no announcement confirming the selinexor plus ruxolitinib submission has been found, and $BBIO stays because filing acceptance for infigratinib is still the next formal step. Month-only and quarter-only windows reflect disclosed guidance and are not exact FDA dates.

Educational content only — not investment advice or a recommendation to buy or sell securities. Verify dates and primary filings before trading around binary events. Full catalyst calendar FDA SEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.